TY - JOUR
T1 - Coronary calcification in SLE
T2 - Comparison with the Multi-Ethnic Study of Atherosclerosis
AU - Kiani, Adnan N.
AU - Magder, Laurence S.
AU - Post, Wendy S.
AU - Szklo, Moyses
AU - Bathon, Joan M.
AU - Schreiner, Pam J.
AU - O'Leary, Daniel
AU - Petri, Michelle
N1 - Publisher Copyright:
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
PY - 2015/8/6
Y1 - 2015/8/6
N2 - Objective. Accelerated atherosclerosis is a major cause of morbidity and death in SLE. The purpose of this study was to determine whether the prevalence and extent of coronary artery calcium (CAC) is higher in female SLE patients compared with a non-SLE sample from the Multi-Ethnic Study of Atherosclerosis (MESA).Methods. CAC was measured in 80 female SLE patients and 241 female MESA controls from the Baltimore Field Centre, ages 45-64 years, without evidence of clinical cardiovascular disease. Binary regression was used to estimate the ratio of CAC prevalence in SLE vs MESA controls, controlling for demographic and cardiovascular risk factors. To compare the groups with respect to the quantity of CAC among those with non-zero Agatston scores, we used linear models in which the outcome was a log-transformed Agatston score.Results. The prevalence of CAC was substantially higher in SLE. The differences were most pronounced and statistically significant in those aged 45-54 years (58% vs 20%, P < 0.0001), but were still observed among those aged 55-65 years (57% vs 36%, P = 0.069). After controlling for age, ethnicity, education, income, diabetes mellitus, hypertension, hyperlipidaemia, high-density lipoprotein levels, smoking, education and BMI, SLE patients still had a significantly higher prevalence of CAC than controls. Among those with CAC, the mean log Agatston score did not differ significantly between SLE and MESA participants.Conclusion. Women with SLE have a higher prevalence of CAC than comparable women without SLE, even after adjusting for traditional cardiovascular risk factors, especially among those aged 45-54 years.
AB - Objective. Accelerated atherosclerosis is a major cause of morbidity and death in SLE. The purpose of this study was to determine whether the prevalence and extent of coronary artery calcium (CAC) is higher in female SLE patients compared with a non-SLE sample from the Multi-Ethnic Study of Atherosclerosis (MESA).Methods. CAC was measured in 80 female SLE patients and 241 female MESA controls from the Baltimore Field Centre, ages 45-64 years, without evidence of clinical cardiovascular disease. Binary regression was used to estimate the ratio of CAC prevalence in SLE vs MESA controls, controlling for demographic and cardiovascular risk factors. To compare the groups with respect to the quantity of CAC among those with non-zero Agatston scores, we used linear models in which the outcome was a log-transformed Agatston score.Results. The prevalence of CAC was substantially higher in SLE. The differences were most pronounced and statistically significant in those aged 45-54 years (58% vs 20%, P < 0.0001), but were still observed among those aged 55-65 years (57% vs 36%, P = 0.069). After controlling for age, ethnicity, education, income, diabetes mellitus, hypertension, hyperlipidaemia, high-density lipoprotein levels, smoking, education and BMI, SLE patients still had a significantly higher prevalence of CAC than controls. Among those with CAC, the mean log Agatston score did not differ significantly between SLE and MESA participants.Conclusion. Women with SLE have a higher prevalence of CAC than comparable women without SLE, even after adjusting for traditional cardiovascular risk factors, especially among those aged 45-54 years.
KW - Agatston score
KW - Atherosclerosis
KW - Cardiovascular
KW - Computed tomography
KW - Coronary artery calcium
KW - Inflammation
KW - MESA
KW - Statins
KW - Systemic lupus erythematosus
KW - cohort
UR - http://www.scopus.com/inward/record.url?scp=84946746469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946746469&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/kev198
DO - 10.1093/rheumatology/kev198
M3 - Article
C2 - 26106213
AN - SCOPUS:84946746469
SN - 1462-0324
VL - 54
SP - 1976
EP - 1981
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 11
ER -